|
|
Home  CMSC Online For MS Professionals MS News Room CMSC INForMS
|
Informs - Main |
|
|
CMSC INForMS
CMSC Industry News For Multiple Sclerosis
- April 16, 2008 - New Data Show Treatment of Multiple Sclerosis (MS) with AVONEX® (interferon Beta-1a) Enhances Quality of Life
- April 15, 2008 - Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX®(interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
- November 8, 2007 - Teva Laquinimod
- November 6, 2007 - BEYOND Results for Multiple Sclerosis Patients
- October 25, 2007 - New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years. Treatment with AVONEX® (Interferon Beta-1a) for Two Years Reduces Probability of Reaching More Severe Disability Milestones at Eight Years
- September 10, 2007 - Landmark Study in Lancet: Patients Treated With Betaseron® After First MS Attack Experienced Significant Delay in MS Progression
- July 3, 2007 - EMD Serono Launches MS LifeLines Access Made Simple, A Program Designed to Simplify Access to MS Therapy
- July 3, 2007 - Opexa Therapeutics Reveals Positive Top-Line Data In Phase I/II Extension Trial With Tovaxin
Disclaimer
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section.
Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites.
CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.
|
|
